Literature DB >> 31664638

Changes in corneal endothelial cell shape after treatment with one drop of ROCK inhibitor.

Riyo Matsumura1,2, Kenji Inoue3, Minako Shiokawa3, Madoka Ono3, Hidenobu Tanihara4, Kyoko Ishida5, Goji Tomita5.   

Abstract

PURPOSE: We performed an investigation of the temporal impact on corneal endothelial cell (CEC) shape after ophthalmic instillation of one drop of the ROCK inhibitor, ripasudil.
METHODS: Subjects comprised 32 healthy adult volunteers, each of whom instilled ripasudil in the right eye. CEC shape [defined as CEC density (CECD), coefficient of variation (CV), and hexagonal cell rate (6A)], central corneal thickness (CCT), intraocular pressure (IOP), and conjunctival hyperemia were evaluated before instillation (baseline) and at 15 min, 1 h, 2 h, and 4-6 h after instillation by non-contact specular microscopy and slit-lamp microscopy. The incidence of pseudo gutta was also assessed.
RESULTS: The CECD (cells/mm2) significantly decreased after instillation as follows: 2661 cells/mm2 at baseline, 2578 cells/mm2 at 15 min, 2527 cells/mm2 at 1 h, 2575 cells/mm2 at 2 h, and 2613 cells/mm2 at 4-6 h. After instillation, CV significantly increased and 6A significantly decreased. Pseudo gutta appeared in 18 subjects (56.3%) after instillation. There was no difference in CCT before and after instillation. IOP significantly decreased after instillation. The most severe conjunctival hyperemia was observed at 15 min after instillation, but had nearly disappeared within 2 h.
CONCLUSIONS: Pseudo gutta appeared in more than half of the subjects, and the CEC shape changed upon instillation of one drop of ripasudil; however, it recovered at 4-6 h after instillation. Therefore, these changes would not greatly impact clinical treatment. Similar to the presence of conjunctival hyperemia, changes in CEC shape occur at early stages after instillation of ripasudil.

Entities:  

Keywords:  Central corneal thickness; Corneal endothelial cells; Pseudo gutta; Ripasudil

Year:  2019        PMID: 31664638     DOI: 10.1007/s10792-019-01198-2

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  15 in total

1.  [Guidelines for the clinical management of allergic conjunctival disease (2nd edition)].

Authors: 
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2010-10

2.  One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.

Authors:  Hiroshi Inazaki; Satoshi Kobayashi; Yoko Anzai; Hisayoshi Satoh; Shimpei Sato; Maiko Inoue; Shin Yamane; Kazuaki Kadonosono
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-15       Impact factor: 3.117

3.  Contribution of actin filaments and microtubules to quasi-in situ tensile properties and internal force balance of cultured smooth muscle cells on a substrate.

Authors:  Kazuaki Nagayama; Takeo Matsumoto
Journal:  Am J Physiol Cell Physiol       Date:  2008-10-15       Impact factor: 4.249

4.  Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.

Authors:  Hidenobu Tanihara; Toshihiro Inoue; Tetsuya Yamamoto; Yasuaki Kuwayama; Haruki Abe; Makoto Araie
Journal:  Am J Ophthalmol       Date:  2013-07-04       Impact factor: 5.258

5.  Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil.

Authors:  Kenji Inoue; Kyoko Ishida; Goji Tomita
Journal:  Jpn J Ophthalmol       Date:  2018-05-24       Impact factor: 2.447

6.  Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.

Authors:  Kenji Inoue; Ryoko Okayama; Minako Shiokawa; Kyoko Ishida; Goji Tomita
Journal:  Int Ophthalmol       Date:  2017-01-06       Impact factor: 2.031

7.  Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study.

Authors:  Riyo Matsumura; Toshihiro Inoue; Akira Matsumura; Hidenobu Tanihara
Journal:  Clin Drug Investig       Date:  2017-06       Impact factor: 2.859

8.  Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.

Authors:  Etsuko Terao; Shunsuke Nakakura; Yasuko Fujisawa; Yuki Fujio; Kanae Matsuya; Yui Kobayashi; Hitoshi Tabuchi; Tsuyoshi Yoneda; Atsuki Fukushima; Yoshiaki Kiuchi
Journal:  Curr Eye Res       Date:  2016-12-02       Impact factor: 2.424

9.  Effect of the Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) on Corneal Endothelial Wound Healing.

Authors:  Naoki Okumura; Yugo Okazaki; Ryota Inoue; Kazuya Kakutani; Shinichiro Nakano; Shigeru Kinoshita; Noriko Koizumi
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-03       Impact factor: 4.799

10.  Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.

Authors:  Hidenobu Tanihara; Toshihiro Inoue; Tetsuya Yamamoto; Yasuaki Kuwayama; Haruki Abe; Makoto Araie
Journal:  JAMA Ophthalmol       Date:  2013-10       Impact factor: 7.389

View more
  1 in total

Review 1.  Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection.

Authors:  Sentaro Kusuhara; Makoto Nakamura
Journal:  Clin Ophthalmol       Date:  2020-05-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.